Rachel Teitelbaum teitelba at
Thu Feb 6 11:26:22 EST 1997

Actually, in the papers they were taking tumor cells from the host, 
transfecting them with the constuct, and reinjecting them to hosts that 
were syngeneic, that had the same tumor.  They got rejection for the 
reason described, they now could see the tumor as foreign, cause some 
cells had B7.  Has this entered the realm of clinical trials?

More information about the Immuno mailing list